APLS Apellis Pharmaceuticals
- 41.990
- -0.530-1.25%
- 42.000
- +0.010+0.02%
Apellis Pharmaceuticals News
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals(APLS.US) Officer Sells US$3.34 Million in Common Stock
$Apellis Pharmaceuticals(APLS.US)$ Officer Deschatelets Pascal sold 78,907 shares of common stock on May 8, 2024 at an average price of $42.3517 for a total value of $3.34 million.Source: Announcement
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
Pascal Deschatelets, Chief Scientific Officer, on May 08, 2024, sold 78,907 shares in Apellis Pharmaceuticals (APLS) for $3,341,848. Following the Form 4 filing with the SEC, Deschatelets has control
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Apellis Pharmaceuticals, Inc., a commerci
Form 144 | Apellis Pharmaceuticals(APLS.US) Officer Proposes to Sell 3.34 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Apellis Pharmaceuticals(APLS.US)$ Officer Deschatelets Pascal intends to sell 78,907 shares of its common stock on May 8, with a total market value of approximately $3.
Apellis Pharmaceuticals Is Maintained at Buy by Citigroup
Apellis Pharmaceuticals Is Maintained at Buy by Citigroup
Apellis Pharmaceuticals Price Target Cut to $60.00/Share From $67.00 by Citigroup
Apellis Pharmaceuticals Price Target Cut to $60.00/Share From $67.00 by Citigroup
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $67 to $60.
Apellis Pharmaceuticals Price Target Maintained With a $92.00/Share by HC Wainwright & Co.
Apellis Pharmaceuticals Price Target Maintained With a $92.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Apellis Pharmaceuticals (APLS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $92.00.
HC Wainwright & Co. : Apellis Pharmaceuticals (APLS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $92.00.
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals with a Buy and maintains $92 price target.
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of their recent
Apellis Stock Sell-off Over Syfovre Sales "Overdone," Says Citi
Unusual Options Activity: TAL, NSC and Others Attract Market Bets, TAL V/OI Ratio Reaches 115.3
EST May 8th Afternoon Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressures
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating.
Apellis Pharmaceuticals Is Maintained at Buy by UBS
Apellis Pharmaceuticals Is Maintained at Buy by UBS
Apellis Pharmaceuticals Price Target Cut to $85.00/Share From $89.00 by UBS
Apellis Pharmaceuticals Price Target Cut to $85.00/Share From $89.00 by UBS
UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85
UBS analyst Eliana Merle maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $89 to $85.
Analysis
Price Target
No Data
